Guizhou Xinbang Pharmaceutical Balance Sheet Health
Financial Health criteria checks 6/6
Guizhou Xinbang Pharmaceutical has a total shareholder equity of CN¥7.1B and total debt of CN¥609.3M, which brings its debt-to-equity ratio to 8.6%. Its total assets and total liabilities are CN¥8.9B and CN¥1.8B respectively. Guizhou Xinbang Pharmaceutical's EBIT is CN¥297.1M making its interest coverage ratio 58.7. It has cash and short-term investments of CN¥752.3M.
Key information
8.6%
Debt to equity ratio
CN¥609.27m
Debt
| Interest coverage ratio | 58.7x |
| Cash | CN¥752.34m |
| Equity | CN¥7.10b |
| Total liabilities | CN¥1.80b |
| Total assets | CN¥8.90b |
Recent financial health updates
Here's Why Guizhou Xinbang Pharmaceutical (SZSE:002390) Can Manage Its Debt Responsibly
Dec 16
These 4 Measures Indicate That Guizhou Xinbang Pharmaceutical (SZSE:002390) Is Using Debt Safely
May 24Recent updates
Here's Why Guizhou Xinbang Pharmaceutical (SZSE:002390) Can Manage Its Debt Responsibly
Dec 16There's No Escaping Guizhou Xinbang Pharmaceutical Co., Ltd.'s (SZSE:002390) Muted Earnings
Sep 26Investors Aren't Buying Guizhou Xinbang Pharmaceutical Co., Ltd.'s (SZSE:002390) Earnings
Jun 26These 4 Measures Indicate That Guizhou Xinbang Pharmaceutical (SZSE:002390) Is Using Debt Safely
May 24Financial Position Analysis
Short Term Liabilities: 002390's short term assets (CN¥5.1B) exceed its short term liabilities (CN¥1.8B).
Long Term Liabilities: 002390's short term assets (CN¥5.1B) exceed its long term liabilities (CN¥40.8M).
Debt to Equity History and Analysis
Debt Level: 002390 has more cash than its total debt.
Reducing Debt: 002390's debt to equity ratio has reduced from 73.1% to 8.6% over the past 5 years.
Debt Coverage: 002390's debt is well covered by operating cash flow (80.8%).
Interest Coverage: 002390's interest payments on its debt are well covered by EBIT (58.7x coverage).
Balance Sheet
Discover healthy companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/27 04:47 |
| End of Day Share Price | 2024/12/27 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Guizhou Xinbang Pharmaceutical Co., Ltd. is covered by 11 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Zhouyu Deng | BOCI Research Ltd. |
| Songtao YE | Changjiang Securities Co. LTD. |
| Yichi Zhang | China International Capital Corporation Limited |